Exicure, Inc. (XCUR)

NCM – Real Time Price. Currency in USD

2.40

-0.12 (-4.76%)

At close: Jun 26, 2026, 4:00 PM EDT

2.39

-0.01 (-0.42%)

After-hours: Jun 26, 2026, 7:48 PM EDT

10.06.2026

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on June 5, 2026 indicating that the Company is not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2.5 million in stockholders' equity.

01.06.2026

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.

22.04.2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas.

02.04.2026

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice: TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS OF EXICURE, INC.

25.03.2026

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

25.03.2026

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.

05.02.2026

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant

Videos

No Data

There is no data to display

Press releases

10.06.2026

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

01.06.2026

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.

22.04.2026

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

02.04.2026

Exicure, Inc. (XCUR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exicure, Inc. (XCUR)

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Videos

No Data

Press releases

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Videos

No Data

Press releases

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Search stocks

Exicure, Inc. (XCUR)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Exicure, Inc. (XCUR)

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Videos

No Data

Press releases

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure, Inc. Reports Full Year 2025 Financial Results

Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant

Videos

No Data

Press releases

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions